Curocell

Curocell Debt Growth

The Year-over-Year Debt Growth of Curocell (372320.KQ) as of Oct 29, 2026 is -13.09 %. In the previous year, Year-over-Year Debt Growth was 49.47 % — a change of -126.46% (lower).

Debt Growth

-13.09 %

YoY

-126.46%

Last updated:

Year-over-Year Debt Growth of Curocell is 2024 -13.09 % . Year-over-Year Debt Growth of Curocell was 2023 49.47 % . It decreases by -126.46% lower compared to the previous year.

The Curocell Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2022
204.95 KRW
Jan 1, 2023
49.47 KRW
Jan 1, 2024
-13.09 KRW
The Curocell Debt Growth history
YEARDebt GrowthYoY
-13.09 %-126.46%
49.47 %-75.86%
204.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curocell Stock analysis

What does Curocell do? Curocell Inc makes money through the development and commercialization of CAR-T therapy technologies for cancer treatment. The company focuses on novel chimeric antigen receptor (CAR)-T therapies targeting specific cancer antigens, improving medicinal effects, reducing side effects, and automating quality analysis. These products are developed for pharmaceutical companies and healthcare providers seeking advanced cancer treatments. The firm's R&D efforts target the biotechnology sector, specifically oncology applications. Curocell Inc's business model centers on creating innovative CAR-T therapies that address unmet medical needs in cancer care. The company's research and development activities are directed at enhancing the efficacy and safety of CAR-T treatments, which are sold to pharmaceutical firms for further development and distribution. The firm's products are positioned within the biotechnology industry, catering to the growing demand for targeted cancer therapies. The company's revenue streams come from the sale of its developed CAR-T technologies to pharmaceutical partners. These partnerships enable the commercialization of Curocell's innovations in the global oncology market. Curocell Inc operates within the biotechnology sector, specifically focusing on the development of next-generation CAR-T therapies for cancer patients. Curocell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curocell stock

Year-over-Year Debt Growth of Curocell is -13.09 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Curocell since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Curocell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Curocell

All Key Metrics — Curocell